IL111920A - Erodible pharmaceutical composition with zero order controlled release - Google Patents
Erodible pharmaceutical composition with zero order controlled releaseInfo
- Publication number
- IL111920A IL111920A IL11192094A IL11192094A IL111920A IL 111920 A IL111920 A IL 111920A IL 11192094 A IL11192094 A IL 11192094A IL 11192094 A IL11192094 A IL 11192094A IL 111920 A IL111920 A IL 111920A
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical composition
- controlled release
- zero order
- order controlled
- erodible
- Prior art date
Links
- 238000013270 controlled release Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 230000003628 erosive effect Effects 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical class OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000003607 modifier Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/166,123 US5393765A (en) | 1993-12-13 | 1993-12-13 | Pharmaceutical compositions with constant erosion volume for zero order controlled release |
Publications (2)
Publication Number | Publication Date |
---|---|
IL111920A0 IL111920A0 (en) | 1995-03-15 |
IL111920A true IL111920A (en) | 1999-08-17 |
Family
ID=22601916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL11192094A IL111920A (en) | 1993-12-13 | 1994-12-07 | Erodible pharmaceutical composition with zero order controlled release |
Country Status (22)
Country | Link |
---|---|
US (1) | US5393765A (ja) |
EP (1) | EP0662322B1 (ja) |
JP (1) | JP2966745B2 (ja) |
KR (1) | KR950016783A (ja) |
CN (1) | CN1110135A (ja) |
AT (1) | ATE214919T1 (ja) |
AU (1) | AU688807B2 (ja) |
BR (1) | BR9404953A (ja) |
CA (1) | CA2136118A1 (ja) |
CO (1) | CO4340618A1 (ja) |
CZ (1) | CZ287718B6 (ja) |
DE (1) | DE69430237T2 (ja) |
ES (1) | ES2171431T3 (ja) |
HU (1) | HU219227B (ja) |
IL (1) | IL111920A (ja) |
NO (1) | NO944803L (ja) |
NZ (1) | NZ270058A (ja) |
PL (1) | PL306245A1 (ja) |
RU (1) | RU2174832C2 (ja) |
TW (1) | TW438597B (ja) |
UA (1) | UA41887C2 (ja) |
ZA (1) | ZA949711B (ja) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5945125A (en) * | 1995-02-28 | 1999-08-31 | Temple University | Controlled release tablet |
US5869079A (en) † | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
US5783212A (en) * | 1996-02-02 | 1998-07-21 | Temple University--of the Commonwealth System of Higher Education | Controlled release drug delivery system |
US5948437A (en) * | 1996-05-23 | 1999-09-07 | Zeneca Limited | Pharmaceutical compositions using thiazepine |
GB9611328D0 (en) * | 1996-05-31 | 1996-08-07 | Zeneca Ltd | Pharmaceutical compositions |
US20050064033A1 (en) * | 1997-04-11 | 2005-03-24 | Notario Gerard F. | Extended release formulations of erythromycin derivatives |
US6551616B1 (en) * | 1997-04-11 | 2003-04-22 | Abbott Laboratories | Extended release formulations of erythromycin derivatives |
US6010718A (en) * | 1997-04-11 | 2000-01-04 | Abbott Laboratories | Extended release formulations of erythromycin derivatives |
US6337091B1 (en) | 1997-10-27 | 2002-01-08 | Temple University - Of The Commonwealth System Of Higher Education | Matrix for controlled delivery of highly soluble pharmaceutical agents |
US6197340B1 (en) * | 1998-05-28 | 2001-03-06 | Medical Research Institute | Controlled release lipoic acid |
US6214381B1 (en) | 1998-09-08 | 2001-04-10 | Effcon, Inc. | Methazolamide composition and method of use |
US20020169145A1 (en) * | 1998-10-14 | 2002-11-14 | Rajen Shah | Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent |
US6555139B2 (en) | 1999-06-28 | 2003-04-29 | Wockhardt Europe Limited | Preparation of micron-size pharmaceutical particles by microfluidization |
US6503528B1 (en) | 1999-11-19 | 2003-01-07 | Abbott Laboratories | Polymeric compositions and a method of making the same |
US6936275B2 (en) | 1999-12-20 | 2005-08-30 | Scolr, Inc. | Amino acid modulated extended release dosage form |
WO2003024427A1 (en) | 1999-12-20 | 2003-03-27 | Temple University Of The Commonwealth System Of Higher Education | Tableted oral extended release dosage form |
US6565882B2 (en) * | 2000-02-24 | 2003-05-20 | Advancis Pharmaceutical Corp | Antibiotic composition with inhibitor |
US6544555B2 (en) * | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
US6242003B1 (en) | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
US20020068078A1 (en) * | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
US6541014B2 (en) * | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
US20020197314A1 (en) * | 2001-02-23 | 2002-12-26 | Rudnic Edward M. | Anti-fungal composition |
US20060127474A1 (en) * | 2001-04-11 | 2006-06-15 | Oskar Kalb | Pharmaceutical compositions comprising fluvastatin |
US20030104052A1 (en) * | 2001-10-25 | 2003-06-05 | Bret Berner | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
CA2409552A1 (en) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
US20030152622A1 (en) * | 2001-10-25 | 2003-08-14 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral diuretic |
US20030091630A1 (en) * | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
AU2003225837B2 (en) * | 2002-03-15 | 2008-11-06 | Forest Laboratories Holdings Limited | NE and 5-HT reuptake inhibitors for treating visceral pain syndromes |
AU2003245504A1 (en) * | 2002-06-14 | 2003-12-31 | Andrx Corporation | Pharmaceutical compositions for drugs having ph-dependentsolubility |
US20060003004A1 (en) * | 2002-10-25 | 2006-01-05 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
US20040121010A1 (en) * | 2002-10-25 | 2004-06-24 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
AU2004207578B2 (en) * | 2003-01-28 | 2007-06-28 | Collegium Pharmaceutical, Inc. | Multiparticulate compositions of milnacipran for oral administration |
US20040185097A1 (en) * | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
US7063862B2 (en) * | 2003-06-03 | 2006-06-20 | Biokey, Inc. | Pharmaceutical composition and method for treating |
EP1638529B1 (en) * | 2003-06-16 | 2016-08-10 | ANDRX Pharmaceuticals, LLC. | Oral extended-release composition |
US8313776B2 (en) * | 2003-07-21 | 2012-11-20 | Shionogi Inc. | Antibiotic product, use and formulation thereof |
AU2004258953B2 (en) * | 2003-07-21 | 2011-02-10 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
EP1648418A4 (en) | 2003-07-21 | 2011-11-16 | Middlebrook Pharmaceuticals Inc | ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION |
EP1653925A1 (en) * | 2003-08-11 | 2006-05-10 | Advancis Pharmaceutical Corporation | Robust pellet |
AU2004264356B2 (en) | 2003-08-12 | 2011-01-27 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
JP5686494B2 (ja) * | 2003-08-29 | 2015-03-18 | シオノギ インコーポレイテッド | 抗生物質製剤、その使用法及び作成方法 |
WO2005027877A1 (en) * | 2003-09-15 | 2005-03-31 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
EP1701705A4 (en) * | 2003-12-24 | 2007-08-08 | Advancis Pharmaceutical Corp | IMPROVED ABSORPTION OF MODIFIED RELEASE DOSAGE FORMS |
JP2008505124A (ja) * | 2004-07-02 | 2008-02-21 | アドバンシス ファーマスーティカル コーポレイション | パルス送達用錠剤 |
US20060024368A1 (en) * | 2004-07-30 | 2006-02-02 | Reza Fassihi | Compressed composite delivery system for release-rate modulation of bioactives |
KR100635301B1 (ko) * | 2004-09-15 | 2006-10-17 | 지엘팜텍 주식회사 | 메실산 독사조신을 함유하는 서방성 정제 |
KR100920856B1 (ko) * | 2004-11-30 | 2009-10-09 | (주)아모레퍼시픽 | 선택적 세로토닌 재흡수 억제제의 연장방출 제제 및 그제조방법 |
US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
US8778924B2 (en) * | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
MX2010004222A (es) * | 2007-10-19 | 2010-09-14 | Purdue Research Foundation | Formulaciones solidas de compuestos cristalinos. |
BRPI1006902A2 (pt) | 2009-01-23 | 2016-02-16 | Aziende Chimiche Riunte Angelini Francesco A C R A F S P A | formulação farmacêutica ou alimentícia de liberação controlada, processo para a produção de uma forma farmacêutica ou alimentícia, sistema de liberação controlada, e, uso de um sistema de liberação controlada |
US9980946B1 (en) | 2017-01-25 | 2018-05-29 | Effcon Laboratories, Inc. | Extended release methazolamide formulation |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3870790A (en) * | 1970-01-22 | 1975-03-11 | Forest Laboratories | Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose |
US4226849A (en) * | 1979-06-14 | 1980-10-07 | Forest Laboratories Inc. | Sustained release therapeutic compositions |
US4259314A (en) * | 1979-12-10 | 1981-03-31 | Hans Lowey | Method and composition for the preparation of controlled long-acting pharmaceuticals |
US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
US4556678A (en) * | 1982-06-24 | 1985-12-03 | Key Pharmaceuticals, Inc. | Sustained release propranolol tablet |
IL70071A (en) * | 1982-11-01 | 1987-12-31 | Merrell Dow Pharma | Multilayered sustained release pharmaceutical tablets having non-uniform distribution of active ingredient |
FR2535202B1 (fr) * | 1982-11-03 | 1985-08-09 | Fabre Sa Pierre | Comprimes de theophylline a liberation controlee et leur procede de fabrication |
US4540566A (en) * | 1984-04-02 | 1985-09-10 | Forest Laboratories, Inc. | Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose |
FR2591105B1 (fr) * | 1985-12-11 | 1989-03-24 | Moet Hennessy Rech | Composition pharmaceutique, notamment dermatologique, ou cosmetique, a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un retinoide ou un analogue structural dudit retinoide tel qu'un carotenoide. |
US4786503A (en) * | 1987-04-06 | 1988-11-22 | Alza Corporation | Dosage form comprising parallel lamine |
US5126145A (en) * | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
DK469989D0 (da) * | 1989-09-22 | 1989-09-22 | Bukh Meditec | Farmaceutisk praeparat |
US5284662A (en) * | 1990-10-01 | 1994-02-08 | Ciba-Geigy Corp. | Oral osmotic system for slightly soluble active agents |
SE9003904D0 (sv) * | 1990-12-07 | 1990-12-07 | Astra Ab | Method for the manufacture of a pharmaceutical dosage form |
KR100205276B1 (ko) * | 1991-10-04 | 1999-07-01 | 가마쿠라 아키오 | 서방성 정제 |
ATE135214T1 (de) * | 1992-02-17 | 1996-03-15 | Siegfried Ag Pharma | Darreichungsformen mit verlaengerter wirkstoffreigabe |
-
1993
- 1993-12-13 US US08/166,123 patent/US5393765A/en not_active Expired - Fee Related
-
1994
- 1994-11-17 TW TW083110673A patent/TW438597B/zh not_active IP Right Cessation
- 1994-11-18 CA CA002136118A patent/CA2136118A1/en not_active Abandoned
- 1994-12-05 ES ES94119113T patent/ES2171431T3/es not_active Expired - Lifetime
- 1994-12-05 EP EP94119113A patent/EP0662322B1/en not_active Expired - Lifetime
- 1994-12-05 AT AT94119113T patent/ATE214919T1/de not_active IP Right Cessation
- 1994-12-05 NZ NZ270058A patent/NZ270058A/xx unknown
- 1994-12-05 DE DE69430237T patent/DE69430237T2/de not_active Expired - Fee Related
- 1994-12-06 AU AU80232/94A patent/AU688807B2/en not_active Ceased
- 1994-12-06 ZA ZA949711A patent/ZA949711B/xx unknown
- 1994-12-07 IL IL11192094A patent/IL111920A/xx not_active IP Right Cessation
- 1994-12-07 HU HU9403496A patent/HU219227B/hu not_active IP Right Cessation
- 1994-12-08 JP JP6330524A patent/JP2966745B2/ja not_active Expired - Fee Related
- 1994-12-12 CO CO94056072A patent/CO4340618A1/es unknown
- 1994-12-12 UA UA94129170A patent/UA41887C2/uk unknown
- 1994-12-12 KR KR1019940033656A patent/KR950016783A/ko active IP Right Grant
- 1994-12-12 BR BR9404953A patent/BR9404953A/pt not_active Application Discontinuation
- 1994-12-12 NO NO944803A patent/NO944803L/no not_active Application Discontinuation
- 1994-12-12 CZ CZ19943127A patent/CZ287718B6/cs not_active IP Right Cessation
- 1994-12-12 CN CN94119315A patent/CN1110135A/zh active Pending
- 1994-12-12 PL PL94306245A patent/PL306245A1/xx unknown
- 1994-12-13 RU RU94043809/14A patent/RU2174832C2/ru not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
UA41887C2 (uk) | 2001-10-15 |
AU8023294A (en) | 1995-06-22 |
CN1110135A (zh) | 1995-10-18 |
HUT75456A (en) | 1997-05-28 |
ATE214919T1 (de) | 2002-04-15 |
EP0662322A2 (en) | 1995-07-12 |
ZA949711B (en) | 1995-08-21 |
JP2966745B2 (ja) | 1999-10-25 |
NO944803L (no) | 1995-06-14 |
JPH07196535A (ja) | 1995-08-01 |
EP0662322B1 (en) | 2002-03-27 |
HU9403496D0 (en) | 1995-02-28 |
CZ312794A3 (en) | 1995-09-13 |
CO4340618A1 (es) | 1996-07-30 |
DE69430237T2 (de) | 2002-07-18 |
RU2174832C2 (ru) | 2001-10-20 |
HU219227B (en) | 2001-03-28 |
US5393765A (en) | 1995-02-28 |
ES2171431T3 (es) | 2002-09-16 |
IL111920A0 (en) | 1995-03-15 |
BR9404953A (pt) | 1995-08-08 |
NZ270058A (en) | 1996-07-26 |
PL306245A1 (en) | 1995-06-26 |
CA2136118A1 (en) | 1995-06-14 |
EP0662322A3 (en) | 1997-01-29 |
NO944803D0 (no) | 1994-12-12 |
DE69430237D1 (de) | 2002-05-02 |
KR950016783A (ko) | 1995-07-20 |
TW438597B (en) | 2001-06-07 |
AU688807B2 (en) | 1998-03-19 |
CZ287718B6 (en) | 2001-01-17 |
RU94043809A (ru) | 1996-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL111920A (en) | Erodible pharmaceutical composition with zero order controlled release | |
MX9706449A (es) | Composicion farmaceutica para compuestos de piperidinalcanol. | |
CA2004598A1 (en) | Medicinal aerosol formulations | |
LV10268A (lv) | Terapeitiski aktivs benzimidazols un ta iegusanas panemiens | |
CA2046069A1 (en) | Treatment of inflammatory diseases with 15-keto-prostaglandin compounds | |
MXPA03005221A (es) | Composicion farmaceutica de dronedarona para administracion parenteral. | |
MY104937A (en) | Cephalosporin derivatives and processes for their preparation | |
ZA881053B (en) | Prostaglandin e1 derivatives as pharmacologically active agents,and pharmaceutical compositions containing these compounds,especially for transcutaneous administration | |
ES2133152T3 (es) | Composicion de tiotepa liofilizada estable. | |
CA2292629A1 (en) | Composition comprising 5-¬4-¬2-(n-methyl-n-2-pyridyl)amino)ethoxy|benzyl|thiazolidine-2,4-dione | |
CA2135179A1 (en) | Pharmaceutical Compositions of Alkylsulphonamides 5HT1 Agonists for Rectal Administration | |
CA2255064A1 (en) | Potassium, sodium and tris oxaprozin salt pharmaceutical formulations | |
CA2361081A1 (en) | Chaperonin 10 and .beta.-interferon therapy of multiple sclerosis | |
ITMI912044A1 (it) | Composizione farmaceutica solida per uso orale a base di dapiprazolo | |
IT1263222B (it) | Composizione farmaceutica per la somministrazione attraverso le mucose. | |
IT1252867B (it) | Composizioni farmaceutiche contenenti progesterone ad elevata biodisponibilita' | |
GR3015840T3 (en) | Use of tumor necrosis factor. | |
MX9601756A (es) | Composicion liquida estable que contiene urato-oxidasa, y composicion liofilizada para su preparacion. | |
CO4340557A1 (es) | Formulaciones farmaceuticas que comprenden derivados del acido clavulanico y su uso | |
AU2670595A (en) | Tocopherol compositions for delivery of biologically active agents | |
IT1271398B (it) | Composizioni farmaceutiche contenenti derivati polipeptidici del ferro per la terapia marziale | |
IE34397L (en) | Therapeutic composition containing benzodiazepine derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
HP | Change in proprietorship | ||
MM9K | Patent not in force due to non-payment of renewal fees |